Advertisement
Recent Conference Coverage
Previous Conference Coverage
Upcoming Conferences
Conference Reports From Other Sources
0
Email
Glossary
The Body Covers: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
Conference Summaries: Day One
Friday, September 27, 2002
Antiretroviral Therapy
Coverage by
Benjamin Young, M.D., Ph.D.
Comparable Antiviral Efficacy and Safety of Lamivudine Administered 300 mg Once-Daily (QD) Versus 150 mg BID both in Combination with Zidovudine (300 mg BID) and Efavirenz (600 mg QD) in HIV-1 Infected, Anitretroviral-Naive Adults: EPV20001 (Abstract H-161)
Substitution of Protease Inhibitors (PI) with Efavirenz (EFV) or Nevirapine (NVP) in Patients with Undetectable Viral Loads: Results of a Retrospective European Multicenter Study (Abstract H-170)
Coverage by
Edwin DeJesus, M.D.
The NEAT Study: GW433908 Efficacy and Safety in Antiretroviral Therapy (ART)-Naive Subjects: Preliminary 24-Week Results (Abstract H-166)
Management of Patients With HIV Infection
Coverage by
Calvin J. Cohen, M.D., M.S.
Management of Patients With Virologic Failure (Abstract 405)
Late Breakers
Coverage by
Edwin DeJesus, M.D.
Favorable Lipid and Mitochondrial (mt) DNA Profile for Tenofovir Disoproxil Fumarate (TDF) Compared to Stavudine (d4T) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral Therapy (ART) Naive Patients: A 48 Week Interim Analysis (Abstract LB-2)
Next Day's Sessions
Return to The Body's coverage of
The
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
.
0
Email
Glossary
Advertisement